官方服务：
资源简介：
Clinical data including the treatment arm, HER2 status Pre- and Post-NAT.EGA dataset EGAD00001009414
应用场景：
创建时间：
2022-09-22
相关数据集
Neoadjuvant anastrozole alone or with gefitinib in early breast cancer. Homo sapiens
Trial 223 was a placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. We used patients from arm B and C: anastrozole 1mg/d for the duration of the 16 week
NIAID Data Ecosystem40
Additional file 6: of HER2 is not a cancer subtype but rather a pan-cancer event and is highly enriched in AR-driven breast tumors
Protein-coding genes associated with HER2 amplification. (A) List of 43 protein-coding genes with subtype-independent expression differences between HER2A and non-HER2A breast tumors, after accounting
Figshare2018-01-31 更新30
Associations between FNA-HER2 of 136 metastatic ALNs and clinicopathologic features of their primary breast cancers.
IHC: immunohistochemistry. aCases with no available results for each characteristic were excluded from data analysis: two cases for primary cancer size, 22 cases for HER2 FISH, and 29 cases for AR and
NIAID Data Ecosystem20
The relationship between tumor location and HER2 status in each cohort.
Abbreviations: HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; ISH, in-situ hybridization; SISH, silver in-situ hybridization; N, number.*HER2 positivity was defined as HER2
Figshare2015-12-02 更新40
Proteomic analysis identifies novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy
Resistance to Human Epidermal Growth Factor Receptor (HER)-targeted cancer therapies appear to be occurring via common pathways, despite differences in their mechanism of action. This suggests that co
NIAID Data Ecosystem20
